US-based biopharmaceutical company Faraday has initiated its first in-human Phase I clinical trial of FDY-5301 as an elemental reducing agent (ERA).

FDY-5301 is Faraday’s lead compound consisting of elemental iodine in its reduced form, iodide, and has been developed to be administered intravenously.

The randomised, double blind, placebo-controlled Phase I trial is intended to test parameters such as safety and tolerability, as well as pharmacokinetics and pharmacodynamics profile of single, escalating doses of intravenously administered FDY-5301 against placebo in healthy subjects.

The trial is being conducted in Australia and is planning to enrol approximately 40 subjects.

"We are working hard on our Phase II preparations in the hope of providing new options to patients as expeditiously as possible."

Faraday CEO Stephen Hill said: "It is gratifying to begin this first-in-human study following the promising preclinical findings to date, and less than six months after our initial 'GLP' toxicity studies were initiated.

“Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We are working hard on our Phase II preparations in the hope of providing new options to patients as expeditiously as possible."

Data from previously held clinical studies suggested the ability of FDY-5301 to reduce reperfusion injury in both cardiac and skeletal muscle in a wide range of various animal models and in multiple species.

The company is focused on the research and development of ERAs, which have potential applications for treatment of critical care illnesses.